<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BRISDELLE- paroxetine mesylateÂ capsuleÂ </strong><br>Noven Therapeutics, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use BRISDELLE safely and effectively. See full prescribing information for BRISDELLE.
			<br><br>BRISDELLE<span class="Sup">Â®</span> (paroxetine) capsules, for oral use
			<br>Initial U.S. Approval: 1992
		</span></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING:  SUICIDAL THOUGHTS AND BEHAVIORS</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete <a href="#SB000">boxed warning</a>.</span></h1>
<ul>
<li><span class="Bold">Potential for increased risk of suicidal thinking and behavior  (<a href="#SB051">5.1</a>)</span></li>
<li><span class="Bold">Monitor for worsening and emergence of suicidal thoughts and behaviors (<a href="#SB051">5.1</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> (<a href="#SB055">5.5</a>)Â Â Â Â  12/2014 </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING:  SUICIDAL THOUGHTS AND BEHAVIORS</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete <a href="#SB000">boxed warning</a>.</span></h1>
<ul>
<li><span class="Bold">Potential for increased risk of suicidal thinking and behavior  (<a href="#SB051">5.1</a>)</span></li>
<li><span class="Bold">Monitor for worsening and emergence of suicidal thoughts and behaviors (<a href="#SB051">5.1</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">BRISDELLE is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of moderate to severe vasomotor symptoms associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (VMS) (<a href="#SB010">1</a>)
									<br><span class="Underline">Limitation of Use</span>: BRISDELLE is not indicated for the treatment of any psychiatric condition (<a href="#SB010">1</a>)
								 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">The recommended dosage of BRISDELLE is 7.5 mg once daily, at bedtime (<a href="#SB021">2.1</a>)
								 </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules:  7.5 mg (<a href="#SB030">3</a>)
								 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Concurrent use with monoamine oxidase inhibitors (MAOI) or use within 14 days of MAOI use (<a href="#SB022">2.2</a>, <a href="#SB041">4.1</a>, <a href="#SB052">5.2</a>, <a href="#SB073">7.3</a>)</li>
<li>Use with thioridazine (<a href="#SB042">4.2</a>, <a href="#SB071">7.1</a>)</li>
<li>Use with pimozide (<a href="#SB043">4.3</a>, <a href="#SB071">7.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any ingredient in BRISDELLE  (<a href="#SB044">4.4</a>)</li>
<li>Pregnancy (<a href="#SB045">4.5</a>, <a href="#SB081">8.1</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>
<span class="Italics">Suicidality</span>: Monitor for suicidality or unusual changes in behavior (<a href="#SB051">5.1</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></span>: <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>, which is potentially life-threatening, has been reported with SSRIs. Discontinue BRISDELLE and initiate supportive treatment (<a href="#SB052">5.2</a>, <a href="#SB073">7.3</a>)</li>
<li>
<span class="Italics">Tamoxifen</span>: Efficacy of tamoxifen may be reduced when administered concomitantly with BRISDELLE (<a href="#SB053">5.3</a>, <a href="#SB071">7.1</a>)</li>
<li>
<span class="Italics">Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span>: Caution patients about the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concomitant use of BRISDELLE and non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, or other drugs that affect coagulation (<a href="#SB054">5.4</a>, <a href="#SB071">7.1</a>)</li>
<li>
<span class="Italics">Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>: </span><span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">Angle closure glaucoma</span> has occurred in patients who have untreated anatomically narrow angles and who are treated with antidepressants. (<a href="#SB055">5.5</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></span>: Can occur in association with syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span> (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>) (<a href="#SB056">5.6</a>)</li>
<li>
<span class="Italics">Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></span>: Epidemiological studies have reported an association between SSRI treatment and <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> (<a href="#SB057">5.7</a>)</li>
<li>
<span class="Italics">Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></span>: Screen for bipolar disorder and monitor for <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> (<a href="#SB058">5.8</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span>: Use cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that potentially lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold (<a href="#SB059">5.9</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></span>: Can occur, most likely in the first few weeks of treatment (<a href="#SB0510">5.10</a>)</li>
<li>
<span class="Italics">Cognitive and Motor Impairment</span>: May cause impairment; patients should not operate machinery or motor vehicles until certain that BRISDELLE does not affect them adversely (<a href="#SB0511">5.11</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (â‰¥ 2%) reported in clinical trials were: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (<a href="#SB061">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Noven Therapeutics, LLC at 1-800-455-8070 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Paroxetine is a strong CYP2D6 inhibitor. Co-administration of BRISDELLE can alter concentrations of other drugs that are metabolized by CYP2D6.  Consider potential drug interactions prior to and during therapy (<a href="#SB053">5.3</a>, <a href="#SB071">7.1</a>, <a href="#SB073">7.3</a>). See Full Prescribing Information for a list of clinically significant drug interactions (<a href="#SB071">7.1</a>, <a href="#SB072">7.2</a>, <a href="#SB073">7.3</a>)
								 </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 12/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING:  SUICIDAL THOUGHTS AND BEHAVIORS</a></h1>
<h1><a href="#section-1" class="toc">1Â Â Â Â Â Â INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2Â Â Â Â Â Â DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1Â Â Â Â Â Â Dosage Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2Â Â Â Â Â Â Use of BRISDELLE Before or After a Monoamine Oxidase Inhibitor (MAOI)</a></h2>
<h1><a href="#section-3" class="toc">3Â Â Â Â Â Â DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4Â Â Â Â Â Â CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1Â Â Â Â Â Â Monoamine Oxidase Inhibitors</a></h2>
<h2><a href="#section-4.2" class="toc">4.2Â Â Â Â Â Â Thioridazine</a></h2>
<h2><a href="#section-4.3" class="toc">4.3Â Â Â Â Â Â Pimozide</a></h2>
<h2><a href="#section-4.4" class="toc">4.4Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any Ingredient in BRISDELLE</a></h2>
<h2><a href="#section-4.5" class="toc">4.5Â Â Â Â Â Â Pregnancy</a></h2>
<h1><a href="#section-5" class="toc">5Â Â Â Â Â Â WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1Â Â Â Â Â Â Suicidal Thoughts and Behaviors</a></h2>
<h2><a href="#section-5.2" class="toc"> 5.2Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3Â Â Â Â Â Â Potential Impact on Tamoxifen Efficacy</a></h2>
<h2><a href="#section-5.4" class="toc">5.4Â Â Â Â Â Â Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="XmChange">5.5Â Â Â Â Â Â Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7Â Â Â Â Â Â Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8Â Â Â Â Â Â Screening Patients for Bipolar Disorder and Monitoring for <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11Â Â Â Â Â Â Potential for Cognitive and Motor Impairment</a></h2>
<h1><a href="#section-6" class="toc">6Â Â Â Â Â Â ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1Â Â Â Â Â Â Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2Â Â Â Â Â Â Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7Â Â Â Â Â Â DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1Â Â Â Â Â Â Potential for BRISDELLE to Affect Other Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2Â Â Â Â Â Â Potential for Other Drugs to Affect BRISDELLE</a></h2>
<h2><a href="#section-7.3" class="toc">7.3Â Â Â Â Â Â Other Potentially Significant Drug Interactions</a></h2>
<h1><a href="#section-8" class="toc">8Â Â Â Â Â Â USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1Â Â Â Â Â Â Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3Â Â Â Â Â Â Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4Â Â Â Â Â Â Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5Â Â Â Â Â Â Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10Â Â Â Â Â Â OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1Â Â Â Â Â Â Human Experience with Overdosage</a></h2>
<h2><a href="#section-9.2" class="toc">10.2Â Â Â Â Â Â Management of Overdosage</a></h2>
<h1><a href="#section-10" class="toc">11Â Â Â Â Â Â DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12Â Â Â Â Â Â CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1Â Â Â Â Â Â Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2Â Â Â Â Â Â Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3Â Â Â Â Â Â Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13Â Â Â Â Â Â NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1Â Â Â Â Â Â Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14Â Â Â Â Â Â CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16Â Â Â Â Â Â HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17Â Â Â Â Â Â PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="SB000"></a><a name="section-1"></a><p></p>
<h1>WARNING:  SUICIDAL THOUGHTS AND BEHAVIORS</h1>
<p class="First"><span class="Bold">Antidepressants, including selective serotonin reuptake inhibitors (SSRIs), have been shown to increase the risk of suicidal thoughts and behavior in pediatric and young adult patients when used to treat major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> and other psychiatric disorders.  Because BRISDELLE is an SSRI, monitor patients closely for worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber <span class="Italics">[see Warnings and Precautions (<a href="#SB051">5.1</a>)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="SB010"></a><a name="section-1"></a><p></p>
<h1>1Â Â Â Â Â Â INDICATIONS AND USAGE</h1>
<p class="First">BRISDELLE is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.<br><br><span class="Underline">Limitation of Use</span>:</p>
<p>BRISDELLE is not indicated for the treatment of any psychiatric condition. BRISDELLE contains a lower dose of paroxetine than that used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span>, <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span>, <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">generalized anxiety disorder</span>, <span class="product-label-link" type="condition" conceptid="440690" conceptname="Social phobia">social anxiety disorder</span>, and post-traumatic stress disorder. The safety and efficacy of this lower dose of paroxetine in BRISDELLE have not been established for any psychiatric condition. Patients who require paroxetine for treatment of a psychiatric condition should discontinue BRISDELLE and initiate a paroxetine-containing medication that is indicated for such use.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="SB020"></a><a name="section-2"></a><p></p>
<h1>2Â Â Â Â Â Â DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB021"></a><a name="section-2.1"></a><p></p>
<h2>2.1Â Â Â Â Â Â Dosage Information</h2>
<p class="First">The recommended dosage of BRISDELLE for the treatment of moderate to severe VMS is 7.5 mg once daily, at bedtime, with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB022"></a><a name="section-2.2"></a><p></p>
<h2>2.2Â Â Â Â Â Â Use of BRISDELLE Before or After a Monoamine Oxidase Inhibitor (MAOI)</h2>
<p class="First">Wait at least 14 days after discontinuation of an MAOI before initiating therapy with BRISDELLE.  Conversely, allow at least 14 days after stopping BRISDELLE before starting an MAOI <span class="Italics">[see Contraindications (<a href="#SB041">4.1</a>), Warnings and Precautions (<a href="#SB052">5.2</a>) and Drug Interactions (<a href="#SB073">7.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="SB030"></a><a name="section-3"></a><p></p>
<h1>3Â Â Â Â Â Â DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">BRISDELLE is available as 7.5 mg pink capsules printed with black edible ink with â€œNOVENâ€? and â€œ7.5 mgâ€? on the capsule.  Each capsule contains 9.69 mg paroxetine mesylate equivalent to 7.5 mg paroxetine base.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="SB040"></a><a name="section-4"></a><p></p>
<h1>4Â Â Â Â Â Â CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB041"></a><a name="section-4.1"></a><p></p>
<h2>4.1Â Â Â Â Â Â Monoamine Oxidase Inhibitors</h2>
<p class="First">Concomitant use of an MAOI with BRISDELLE or within 14 days of stopping treatment with BRISDELLE is contraindicated because of an increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.  The use of BRISDELLE within 14 days of stopping an MAOI is also contraindicated <span class="Italics">[see Dosage and Administration (<a href="#SB022">2.2</a>), Warnings and Precautions (<a href="#SB052">5.2</a>) and Drug Interactions (<a href="#SB073">7.3</a>)]</span>.</p>
<p>Starting BRISDELLE in a patient who is being treated with linezolid or intravenous methylene blue, both of which inhibit monoamine oxidase, is also contraindicated because of an increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> <span class="Italics">[see Dosage and Administration (<a href="#SB022">2.2</a>), Warnings and Precautions (<a href="#SB052">5.2</a>) and Drug Interactions (<a href="#SB073">7.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB042"></a><a name="section-4.2"></a><p></p>
<h2>4.2Â Â Â Â Â Â Thioridazine</h2>
<p class="First">Concomitant use of BRISDELLE with thioridazine is contraindicated, because thioridazine prolongs the QT interval, and paroxetine can increase thioridazine levels <span class="Italics">[see Drug Interactions (<a href="#SB071">7.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB043"></a><a name="section-4.3"></a><p></p>
<h2>4.3Â Â Â Â Â Â Pimozide</h2>
<p class="First">Concomitant use of BRISDELLE with pimozide is contraindicated because pimozide prolongs the QT interval, and paroxetine increases pimozide levels <span class="Italics">[see Drug Interactions (<a href="#SB071">7.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB044"></a><a name="section-4.4"></a><p></p>
<h2>4.4Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any Ingredient in BRISDELLE</h2>
<p class="First">BRISDELLE is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to paroxetine or any of the other ingredients in BRISDELLE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB045"></a><a name="section-4.5"></a><p></p>
<h2>4.5Â Â Â Â Â Â Pregnancy</h2>
<p class="First">Menopausal VMS does not occur during pregnancy and BRISDELLE may cause fetal harm <span class="Italics">[see Use in Specific Populations (<a href="#SB081">8.1</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="SB050"></a><a name="section-5"></a><p></p>
<h1>5Â Â Â Â Â Â WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB051"></a><a name="section-5.1"></a><p></p>
<h2>5.1Â Â Â Â Â Â Suicidal Thoughts and Behaviors</h2>
<p class="First">BRISDELLE is not approved for any psychiatric condition.</p>
<p>Antidepressants, including those that contain an SSRI, increase the risk of suicidal thinking and behavior (suicidality) in pediatric and young adult patients when used to treat major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. There is limited information regarding suicidality in women who use BRISDELLE for treatment of VMS. The BRISDELLE trials excluded women with a presence or history of previous psychiatric disorders.</p>
<p>Consider discontinuing BRISDELLE in patients with worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or those who experience emergent suicidality or symptoms that might be precursors to worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patientâ€™s presenting symptoms.</p>
<p><span class="Bold">All patients being treated with BRISDELLE should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of treatment.</span></p>
<p><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> have been reported in patients being treated with antidepressants for MDD as well as for other psychiatric and nonpsychiatric indications. Although a causal link between the emergence of such symptoms and either the worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.</p>
<p><span class="Bold">Families and caregivers of patients being treated with BRISDELLE should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers.  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB052"></a><a name="section-5.2"></a><p></p>
<h2> 5.2Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> has been reported with SSRIs, including paroxetine, alone but particularly with concomitant use of serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. Johnâ€™s Wort), and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and others such as linezolid and intravenous methylene blue).</p>
<p><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular symptoms (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). Monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</p>
<p>The concomitant use of BRISDELLE with MAOIs is contraindicated. Do not start BRISDELLE in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking BRISDELLE. BRISDELLE should be discontinued before initiating treatment with the MAOI <span class="Italics">[see Contraindications (<a href="#SB041">4.1</a>) and Dosage and Administration (<a href="#SB022">2.2</a>)]</span>.</p>
<p>If concomitant use of BRISDELLE with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. Johnâ€™s Wort) is clinically warranted, consider the increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> and carefully observe the patient, particularly during treatment initiation <span class="Italics">[see Contraindications (<a href="#SB041">4.1</a>) Drug Interactions (<a href="#SB073">7.3</a>)]</span>.  </p>
<p><span class="Bold">Discontinue BRISDELLE and any concomitant serotonergic agents immediately if the above events occur and initiate supportive symptomatic treatment.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB053"></a><a name="section-5.3"></a><p></p>
<h2>5.3Â Â Â Â Â Â Potential Impact on Tamoxifen Efficacy</h2>
<p class="First">It is uncertain whether the co-administration of paroxetine and tamoxifen has a significant adverse effect on the efficacy of tamoxifen. Some studies have shown that the efficacy of tamoxifen, as measured by the risk of breast cancer relapse/mortality, may be reduced when co-prescribed with paroxetine as a result of paroxetineâ€™s irreversible inhibition of CYP2D6 <span class="Italics">[see Drug Interactions (<a href="#SB071">7.1</a>)]</span>. However, other studies have failed to demonstrate such a risk. When tamoxifen is used for the treatment or prevention of breast cancer, weigh the likely benefit of BRISDELLE for treating VMS vs. the risk of possible decreased tamoxifen effectiveness, and consider avoiding the concomitant use of BRISDELLE for VMS treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB054"></a><a name="section-5.4"></a><p></p>
<h2>5.4Â Â Â Â Â Â Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">SSRIs, including BRISDELLE, may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events related to SSRIs have ranged from <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> to life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>. Caution patients about the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concomitant use of BRISDELLE and NSAIDs, aspirin, or other drugs that affect coagulation <span class="Italics">[see Drug Interactions (<a href="#SB071">7.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB055"></a><a name="section-5.5"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.5Â Â Â Â Â Â Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The pupillary dilation that occurs following use of many antidepressants and BRISDELLE may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB056"></a><a name="section-5.6"></a><p></p>
<h2>5.6Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> may occur as a result of treatment with SSRIs, including BRISDELLE. Elderly patients may be at greater risk. In many cases, the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> appears to be the result of the syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span> (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>). Cases with serum sodium lower than 110 mmol/L have been reported in patients using SSRIs. Also, patients taking diuretics or who are volume-depleted can be at greater risk. Consider discontinuation of BRISDELLE in patients with symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and institute appropriate medical intervention.</p>
<p>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span>, which can lead to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>. Signs and symptoms associated with more severe and/or acute cases have included <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB057"></a><a name="section-5.7"></a><p></p>
<h2>5.7Â Â Â Â Â Â Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></h2>
<p class="First">Epidemiological studies on bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> risk following exposure to SSRIs have reported an association between SSRI treatment and <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>. It is unknown to what extent <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> risk is directly attributable to SSRI treatment.  If a BRISDELLE-treated patient presents with unexplained <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, point <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, consider the possibility of a fragility <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB058"></a><a name="section-5.8"></a><p></p>
<h2>5.8Â Â Â Â Â Â Screening Patients for Bipolar Disorder and Monitoring for <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></h2>
<p class="First">BRISDELLE is only indicated for the treatment of moderate to severe VMS and is not approved for use in treating either <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="436665" conceptname="Bipolar disorder">bipolar depression</span>. However, prior to initiating treatment with BRISDELLE, all patients should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. It is generally believed (though not established in controlled trials) that use of an antidepressant alone may increase the likelihood of precipitation of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in patients at risk for bipolar disorder.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB059"></a><a name="section-5.9"></a><p></p>
<h2>5.9Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">In premarketing testing of paroxetine, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occurred in 0.1% of paroxetine-treated patients. Use BRISDELLE cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that potentially lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. Evaluate and consider discontinuing use in any patient who develops <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB0510"></a><a name="section-5.10"></a><p></p>
<h2>5.10Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></h2>
<p class="First">The use of paroxetine or other SSRIs has been associated with the development of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, which is characterized by an inner sense of <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor agitation</span> such as an inability to sit or stand still usually associated with subjective distress. This is most likely to occur within the first few weeks of treatment.  Discontinue treatment with BRISDELLLE if <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB0511"></a><a name="section-5.11"></a><p></p>
<h2>5.11Â Â Â Â Â Â Potential for Cognitive and Motor Impairment</h2>
<p class="First">BRISDELLE has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that the drug treatment does not affect them adversely.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="SB060"></a><a name="section-6"></a><p></p>
<h1>6Â Â Â Â Â Â ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in labeling:</p>
<ul>
<li>Suicidality <span class="Italics">[see Warnings and Precautions (<a href="#SB051">5.1</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> <span class="Italics">[see Warnings and Precautions (<a href="#SB052">5.2</a>)]</span>
</li>
<li>Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#SB054">5.4</a>)]</span>
</li>
<li>Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> [see Warnings and Precautions (<a href="#SB055">5.5</a>)]</li>
<li><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> <span class="Italics">[see Warnings and Precautions (<a href="#SB056">5.6</a>)]</span>
</li>
<li>Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span> <span class="Italics">[see Warnings and Precautions (<a href="#SB057">5.7</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span> <span class="Italics">[see Warnings and Precautions (<a href="#SB058">5.8</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> <span class="Italics">[see Warnings and Precautions (<a href="#SB059">5.9</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> <span class="Italics">[see Warnings and Precautions (<a href="#SB0510">5.10</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="34092-7">
<a name="SB061"></a><a name="section-6.1"></a><p></p>
<h2>6.1Â Â Â Â Â Â Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot directly be compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to BRISDELLE in the one 8-week Phase 2 randomized, placebo-controlled trial and the two Phase 3 randomized, placebo-controlled, 12-week and 24-week trials for the treatment of moderate to severe VMS <span class="Italics">[see Clinical Studies (<a href="#SB140">14</a>)]</span>. In these trials, a total of 635 women were exposed to BRISDELLE 7.5 mg administered orally once daily and 641 women received placebo. The majority of BRISDELLE-treated patients were Caucasian (68%) and African American (30%), with a mean age of 55 years (range 40 to 73 years).  Women with a history of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> or <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> were excluded from these studies.  </p>
<p><span class="Underline">Adverse Reactions Leading to Study Discontinuation</span>: A total of 4.7% of women taking BRISDELLE discontinued from the clinical trials due to an adverse reaction, compared to 3.7% of women on placebo; the most frequent adverse reactions leading to discontinuation among paroxetine-treated women were: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (0.3%), attention disturbances (0.3%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (0.3%), and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> (0.3%).</p>
<p><span class="Underline">Common Adverse Reactions</span>: Overall, based on investigatorsâ€™ determinations about what events were likely to be drug-related, about 20% of women treated with BRISDELLE reported at least 1 adverse reaction in the three controlled studies. The most common adverse reactions (â‰¥ 2% and more common among BRISDELLE-treated women) reported in these studies were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>/<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>/<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Of these commonly reported adverse reactions, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> occurred primarily within the first 4 weeks of treatment and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> occurred primarily within the first week of treatment, and decreased in frequency with continued therapy.</p>
<p>The adverse reactions that occurred in at least 2% of patients in the BRISDELLE group and at a higher incidence than placebo are shown in <a href="#Table1">Table 1</a> for the pooled Phase 2 and Phase 3 trials.</p>
<a name="Table1"></a><table width="600">
<caption><span>Table 1Â Â Â Â Â Â Frequency of Adverse Reactions in the Phase 2 and Phase 3 Trials (â‰¥ 2% and at a higher incidence than placebo)  </span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" rowspan="2"><span class="Bold">Â </span></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><span class="Bold">Frequency n (%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">BRISDELLE (n = 635)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">Placebo (n = 641)</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule" align="center">40 (6.3)</td>
<td class="Botrule Lrule Rrule" align="center">31 (4.8)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><span class="Bold">General disorders and administration site conditions</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span></td>
<td class="Botrule Lrule Rrule" align="center">31 (4.9)</td>
<td class="Botrule Lrule Rrule" align="center">18 (2.8)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td class="Botrule Lrule Rrule" align="center">27 (4.3)</td>
<td class="Botrule Lrule Rrule" align="center">15 (2.3)</td>
</tr>
</tbody>
</table>
<p>Certain symptoms were seen more frequently in women at the time of discontinuation of BRISDELLE compared to women discontinuing placebo, and have also been reported upon discontinuation of other formulations of paroxetine, particularly when abrupt. These include increased dreaming/<span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>/<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>/<span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>/<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span> feeling in legs, and trouble sleeping/<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms with other formulations of paroxetine.</p>
<p><span class="Underline">Serious Adverse Reactions</span>: In the pooled Phase 2 and Phase 3 trials, three BRISDELLE-treated patients reported a serious adverse reaction of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and one BRISDELLE-treated patient reported a serious adverse reaction of <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>. There were no serious adverse reactions of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> or <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> reported among the placebo-treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB062"></a><a name="section-6.2"></a><p></p>
<h2>6.2Â Â Â Â Â Â Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified from clinical studies of paroxetine and during post-approval use of other formulations of paroxetine. Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Underline">Blood and Lymphatic System Disorders</span>: <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</span>, Events related to impaired hematopoiesis (including <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">Ventricular fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">Ventricular tachycardia</span> (including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4185268" conceptname="Acute hemorrhagic pancreatitis">Pancreatitis hemorrhagic</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>.</p>
<p><span class="Underline">General Disorders and Administration Site Conditions</span>: <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, <span class="product-label-link" type="condition" conceptid="441260" conceptname="Drug withdrawal">Drug withdrawal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span>.</p>
<p><span class="Underline">Hepatobiliary Disorders</span>: Drug-induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span>.</p>
<p><span class="Underline">Investigations</span>: Elevated liver tests (the most severe cases were <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>, and grossly elevated transaminases associated with severe liver dysfunction).</p>
<p><span class="Underline">Metabolism and Nutrition Disorders</span>: <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus inadequate control, Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic malignant syndrome</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span>.</p>
<p><span class="Underline">Psychiatric Disorders</span>: <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggression</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">Disorientation</span>, <span class="product-label-link" type="condition" conceptid="4024763" conceptname="Homicidal thoughts">Homicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>.</p>
<p><span class="Underline">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary hypertension</span>. </p>
<p><span class="Underline">Skin and Subcutaneous Tissue Disorders</span>: <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="SB070"></a><a name="section-7"></a><p></p>
<h1>7Â Â Â Â Â Â DRUG INTERACTIONS</h1>
<p class="First">No drug-drug interaction studies have been conducted with BRISDELLE.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="SB071"></a><a name="section-7.1"></a><p></p>
<h2>7.1Â Â Â Â Â Â Potential for BRISDELLE to Affect Other Drugs</h2>
<p class="First">Paroxetine is a strong CYP2D6 inhibitor. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 <span class="Italics">[see Clinical Pharmacology (<a href="#SB123">12.3</a>)]</span>. <a href="#Table2">Table 2</a> contains examples of drugs with a metabolism that may be affected by co-administration with BRISDELLE.</p>
<a name="Table2"></a><table width="750">
<caption><span>Table 2 Â Â Â Â Â Â Effects of Paroxetine on Other Drugs</span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">Concomitant <br>Drug Name</span><br><br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Effect of Paroxetine on <br>Other Drugs</span></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Clinical Recommendations</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Thioridazine<br><br><br><br>
</td>
<td class="Botrule Lrule Rrule" valign="top">Increased plasma concentrations of thioridazine <br><br>Potential QTc prolongation</td>
<td class="Botrule Lrule Rrule" valign="top">Concomitant use of thioridazine and BRISDELLE is <br>contraindicated.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Pimozide<br><br><br><br>
</td>
<td class="Botrule Lrule Rrule" valign="top">Increased plasma concentrations <br>of pimozide. Potential QTc <br>prolongation</td>
<td class="Botrule Lrule Rrule" valign="top">Concomitant use of pimozide and BRISDELLE is <br>contraindicated.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Tamoxifen<br><br><br>
</td>
<td class="Botrule Lrule Rrule" valign="top">Reduced plasma concentrations <br>of active tamoxifen metabolite</td>
<td class="Botrule Lrule Rrule" valign="top">Consider avoiding concomitant use of tamoxifen <br>and BRISDELLE.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle">
<br>Tricyclic <br>Antidepressant <br>(TCA)<br>(e.g., Desipramine)<br><br>
</td>
<td class="Botrule Lrule Rrule" valign="top">Increased plasma concentrations <br>and elimination half-life</td>
<td class="Botrule Lrule Rrule" valign="top">Plasma TCA concentrations may need to be <br>monitored and the dose of TCA may need to be <br>reduced if a TCA is co-administered with <br>BRISDELLE. Monitor tolerability.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Risperidone<br><br><br><br>
</td>
<td class="Botrule Lrule Rrule" valign="top">Increased plasma concentrations <br>of risperidone</td>
<td class="Botrule Lrule Rrule" valign="top">A lower dosage of risperidone may be necessary <br>(see the Full Prescribing Information for <br>risperidone). Monitor tolerability.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Atomoxetine<br><br><br><br>
</td>
<td class="Botrule Lrule Rrule" valign="top">Increased exposure of <br>atomoxetine</td>
<td class="Botrule Lrule Rrule" valign="top">A lower dosage of atomoxetine may be necessary <br>(see Full Prescribing Information for atomoxetine). <br>Monitor tolerability.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Drugs Highly Bound <br>to Plasma Protein <br>(e.g., Warfarin)<br><br>
</td>
<td class="Botrule Lrule Rrule" valign="top">Increased free plasma <br>concentrations</td>
<td class="Botrule Lrule Rrule" valign="top">The dosage of warfarin may need to be reduced.  <br>Monitor tolerability and the International <br>Normalized Ratio.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Digoxin<br><br><br>
</td>
<td class="Botrule Lrule Rrule" valign="top">Decreased plasma concentrations <br>of digoxin </td>
<td class="Botrule Lrule Rrule" valign="top">Dosage of digoxin may need to be increased.  <br>Monitor digoxin concentrations and clinical effect.</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">Theophylline<br><br><br><br>
</td>
<td class="Botrule Lrule Rrule" valign="top">Increased plasma concentrations <br>of theophylline </td>
<td class="Botrule Lrule Rrule" valign="top">Dosage of theophylline may need to be decreased. <br>Monitor theophylline concentrations and <br>tolerability.</td>
</tr>
</tbody>
</table>
<p>Use caution if co-administering BRISDELLE with other drugs that are metabolized by CYP2D6, including nortriptyline, amitriptyline, imipramine, desipramine, fluoxetine, phenothiazines, risperidone, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB072"></a><a name="section-7.2"></a><p></p>
<h2>7.2Â Â Â Â Â Â Potential for Other Drugs to Affect BRISDELLE</h2>
<p class="First">The metabolism and pharmacokinetics of paroxetine may be affected by the induction and inhibition of drug metabolizing enzymes such as CYP2D6. <a href="#Table3">Table 3</a> contains a list of drugs that may affect the pharmacokinetics of BRISDELLE when administered concomitantly <span class="Italics">[see Clinical Pharmacology (<a href="#SB123">12.3</a>)]</span>.</p>
<a name="Table3"></a><table width="650">
<caption><span>Table 3 Â Â Â Â Â Â Effects of Other Drugs on Paroxetine</span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">Concomitant <br>Drug Name</span><br><br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">Effect of Concomitant Drug <br>on Paroxetine</span><br><br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">Clinical Recommendations</span><br><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Phenobarbital<br><br>
</td>
<td class="Botrule Lrule Rrule" valign="top">Decreased paroxetine exposure<br>
</td>
<td class="Lrule Rrule">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle">
<br><br>Phenytoin<br><br>
</td>
<td class="Botrule Lrule Rrule" valign="middle">Decreased  paroxetine exposure<br><br>
</td>
<td class="Lrule Rrule">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle">
<br><br>Fosamprenavir/ <br>Ritonavir<br><br><br>
</td>
<td class="Botrule Lrule Rrule" valign="middle">Decreased plasma concentration <br>of paroxetine</td>
<td class="Lrule Rrule" valign="top">No dose adjustment for BRISDELLE.<br><br>Monitor clinical effect of BRISDELLE.</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">Cimetidine</td>
<td class="Botrule Lrule Rrule" valign="top">Increased plasma concentration <br>of paroxetine<br><br>
</td>
<td class="Botrule Lrule Rrule">Â </td>
</tr>
</tbody>
</table>
<p>Use caution if co-administering BRISDELLE with other drugs that inhibit CYP2D6 (e.g., quinidine).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB073"></a><a name="section-7.3"></a><p></p>
<h2>7.3Â Â Â Â Â Â Other Potentially Significant Drug Interactions</h2>
<p class="First"><span class="Underline">Monoamine Oxidase Inhibitors (MAOIs)</span><br>Serious adverse reactions such as <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported in patients receiving a concomitant SSRI and MAOI, in patients started on an SSRI who recently received an MAOI and in patients started on an MAOI who recently received an SSRI. Therefore, concomitant use of MAOIs with BRISDELLE or use of BRISDELLE and an MAOI within 14 days of each other is contraindicated <span class="Italics">[see Dosage and Administration (<a href="#SB022">2.2</a>), Contraindications (<a href="#SB041">4.1</a>) and Warnings and Precautions (<a href="#SB052">5.2</a>)]</span>.</p>
<p><span class="Underline">Serotonergic Drugs</span><br>If concomitant use of BRISDELLE with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. Johnâ€™s Wort) is clinically warranted, consider the increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> and carefully observe the patient, particularly during treatment initiation  <span class="Italics">[see Warnings and Precautions (<a href="#SB052">5.2</a>)]</span>. </p>
<p>An interaction between paroxetine and tryptophan may occur when they are co-administered. Adverse experiences, consisting primarily of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, have been reported when tryptophan was administered to patients taking paroxetine. Consequently, concomitant use of BRISDELLE with tryptophan is not recommended.</p>
<p>If concomitant use of BRISDELLE with a serotonergic drug is warranted, carefully observe the patient, particularly during treatment initiation. There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the use of an SSRI and a triptan. </p>
<p>BRISDELLE contains paroxetine, which is also the active ingredient in other drugs. The concomitant use of BRISDELLE with other paroxetine products is not recommended <span class="Italics">[see Indications and Usage (<a href="#SB010">1</a>)]</span>.</p>
<p><span class="Underline">Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)</span><br>Altered anticoagulant effects, including increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, have been reported when SSRIs are co-administered with NSAIDs, aspirin, and warfarin or other drugs that affect coagulation. There may be a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> between paroxetine and warfarin that causes an increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis despite unaltered <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. Carefully monitor patients receiving warfarin therapy when BRISDELLE is initiated or discontinued <span class="Italics">[see Warnings and Precautions (<a href="#SB054">5.4</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="SB080"></a><a name="section-8"></a><p></p>
<h1>8Â Â Â Â Â Â USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="SB081"></a><a name="section-8.1"></a><p></p>
<h2>8.1Â Â Â Â Â Â Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category X </span></p>
<p><span class="Italics">Risk Summary</span></p>
<p>BRISDELLE is contraindicated in pregnant women because menopausal VMS does not occur during pregnancy and paroxetine can cause fetal harm. Epidemiological studies have shown that infants exposed to paroxetine in the first trimester of pregnancy may have an increased risk of cardiovascular malformations. Cardiac malformations are a common congenital abnormality. These data would suggest that the risk of a cardiac abnormality following paroxetine exposure in the first trimester may increase the risk from 1% to 2%. Exposure to SSRIs in late pregnancy may lead to an increased risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding, and/or persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn (PPHN). No <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was seen in reproductive development studies conducted in rats and rabbits. However, an increase in rat pup <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> was seen during the first 4 days of lactation when dosing occurred during the last trimester of gestation and continued throughout lactation, at a dose approximately equal to the maximum recommended human dose (MRHD) for VMS (7.5 mg) on an mg/m<span class="Sup">2</span> basis. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.</p>
<p><span class="Italics">Human Data</span></p>
<p><span class="Underline">First-Trimester Pregnancy Exposure</span></p>
<ul><li>Epidemiologic studies which include data from the Swedish National Registry, a retrospective cohort study using United Healthcare data and a meta-analysis of studies (1992-2008) have shown a less than 2-fold  increased risk of cardiac malformations, primarily ventricular septal and <span class="product-label-link" type="condition" conceptid="4289309" conceptname="Atrial septal defect">atrial septal defects</span>, with first-trimester paroxetine exposure. Two case-control studies using separate databases with &gt; 9000 birth defect cases and &gt; 4000 controls showed 7 and 6 paroxetine-exposed infants respectively, with right ventricular outflow tract obstructions, a 2- to 3-fold increased risk. An increase in overall congenital malformations with first-trimester paroxetine use was not observed in all studies.</li></ul>
<p><span class="Underline">Third-Trimester Pregnancy Exposure</span></p>
<ul>
<li>Neonates exposed to SSRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, temperature instability, feeding difficulty, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and constant <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>. These features are consistent with either a direct toxic effect of SSRIs or, possibly, a drug discontinuation syndrome. It should be noted that in some cases, the clinical picture is consistent with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> <span class="Italics">[see Warnings and Precautions (<a href="#SB052">5.2</a>)]</span>.</li>
<li>Infants exposed to SSRIs in late pregnancy may have an increased risk for persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn (PPHN). PPHN occurs in 1 â€“ 2 per 1000 live births in the general population and is associated with substantial neonatal morbidity and mortality. In a retrospective case-control study of 377 women whose infants were born with PPHN and 836 women whose infants were born healthy, the risk for developing PPHN was approximately 6-fold higher for infants exposed to SSRIs after the 20th week of gestation compared to infants who had not been exposed to antidepressants during pregnancy. There is currently no corroborative evidence regarding the risk for PPHN following exposure to SSRIs in pregnancy; this is the first study that has investigated the potential risk. The study did not include enough cases with exposure to individual SSRIs to determine if all SSRIs posed similar levels of PPHN risk. </li>
</ul>
<p><span class="Italics Underline">Animal Data</span></p>
<p>Reproduction studies were performed at doses up to 50 mg/kg/day in rats and 6 mg/kg/day in rabbits administered during organogenesis. These doses are approximately 65 (rat) and 16 (rabbit) times the maximum recommended human dose (MRHD) for VMS on an mg/m<span class="Sup">2</span> basis. There were no teratogenic effects. However, in rats, there was an increase in pup <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> during the first 4 days of lactation when dosing occurred during the last trimester of gestation and continued throughout lactation. This effect occurred at a dose of 1 mg/kg/day or approximately equal to the MRHD for VMS on an mg/m<span class="Sup">2</span> basis. The no-effect dose for rat pup mortality was not determined. The cause of these <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="SB083"></a><a name="section-8.2"></a><p></p>
<h2>8.3Â Â Â Â Â Â Nursing Mothers</h2>
<p class="First">Paroxetine is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from BRISDELLE, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="SB084"></a><a name="section-8.3"></a><p></p>
<h2>8.4Â Â Â Â Â Â Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established; BRISDELLE is not indicated in the pediatric population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="SB085"></a><a name="section-8.4"></a><p></p>
<h2>8.5Â Â Â Â Â Â Geriatric Use</h2>
<p class="First">Clinical studies of BRISDELLE did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Elderly patients may have elevated paroxetine plasma concentrations compared to younger patients. However, no BRISDELLE dose adjustment is considered necessary in elderly patients <span class="Italics">[see Clinical Pharmacology (<a href="#SB123">12.3</a>)]</span>.</p>
<p>SSRIs have been associated with cases of clinically significant <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in elderly patients, who may be at greater risk for this adverse event <span class="Italics">[see Warnings and Precautions (<a href="#SB056">5.6</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB086"></a><a name="section-8.5"></a><p></p>
<h2>8.6Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No BRISDELLE dose adjustment is considered necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Clinical Pharmacology (<a href="#SB123">12.3</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB087"></a><a name="section-8.6"></a><p></p>
<h2>8.7Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No BRISDELLE dose adjustment is considered necessary in patients with liver impairment <span class="Italics">[see Clinical Pharmacology (<a href="#SB123">12.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="SB100"></a><a name="section-9"></a><p></p>
<h1>10Â Â Â Â Â Â OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB101"></a><a name="section-9.1"></a><p></p>
<h2>10.1Â Â Â Â Â Â Human Experience with Overdosage</h2>
<p class="First">There is limited clinical experience with BRISDELLE overdosage in humans, as there were no <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> reported in the clinical studies.  </p>
<p>Spontaneous cases of deliberate or accidental overdosage during paroxetine treatment have been reported; some of these cases were fatal and some of the fatalities appeared to involve paroxetine alone. Of nonfatal cases with known outcome, most recovered without sequelae. The largest known ingestion involved 2000 mg of paroxetine (267 times the maximum recommended daily dose) in a patient who recovered.  </p>
<p>Commonly reported adverse reactions associated with paroxetine overdosage include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. Other notable signs and symptoms observed with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> involving paroxetine (alone or with other substances) include <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> (including <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>), ventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> (including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reactions</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, symptoms of hepatic dysfunction (including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, and <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>), <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reactions</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB102"></a><a name="section-9.2"></a><p></p>
<h2>10.2Â Â Â Â Â Â Management of Overdosage</h2>
<p class="First">Treatment should consist of those general measures employed in the management of overdosage with any SSRI. Consult with a certified poison control center for up-to-date guidance and advice on treatment of overdosage.</p>
<p>Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is not recommended. In managing overdosage, consider the possibility of multiple drug involvement. </p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="SB110"></a><a name="section-10"></a><p></p>
<h1>11Â Â Â Â Â Â DESCRIPTION</h1>
<p class="First">BRISDELLE (paroxetine) is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of moderate to severe VMS associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. It is identified chemically as (-)-<span class="Italics">trans</span> -4R- (4â€™-fluorophenyl) - 3S - [(3â€™, 4â€™-methylenedioxyphenoxy) methyl] piperidine mesylate and has the empirical formula of C<span class="Sub">19</span>H<span class="Sub">20</span>FNO<span class="Sub">3</span>â€¢CH<span class="Sub">3</span>SO<span class="Sub">3</span>H. The molecular weight is 425.5 (329.4 as free base). The structural formula is: </p>
<p><img alt="paroxetine structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf208751-e6d8-11e1-aff1-0800200c9a66&amp;name=brisdelle-figure-1.jpg"></p>
<p>The mesylate salt of paroxetine is an odorless, off-white powder, having a melting point range of 147Â° to 150Â°C and a solubility of more than 1 g/mL in water. </p>
<p>Each pink capsule contains 9.69 mg paroxetine mesylate equivalent to 7.5 mg paroxetine base.</p>
<p>Inactive ingredients consist of: dibasic calcium phosphate, sodium starch glycolate, magnesium stearate, gelatin, titanium dioxide, FD&amp;C Yellow #6, FD&amp;C Red #3, FD&amp;C Red #40, shellac, and black iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="SB120"></a><a name="section-11"></a><p></p>
<h1>12Â Â Â Â Â Â CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="SB121"></a><a name="section-11.1"></a><p></p>
<h2>12.1Â Â Â Â Â Â Mechanism of Action</h2>
<p class="First">Nonclinical studies have shown that paroxetine is an SSRI. BRISDELLE is not an estrogen, and its mechanism of action for the treatment of VMS is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="SB122"></a><a name="section-11.2"></a><p></p>
<h2>12.2Â Â Â Â Â Â Pharmacodynamics</h2>
<p class="First">Studies at clinically relevant doses in humans have demonstrated that paroxetine blocks the uptake of serotonin into human platelets. <span class="Italics">In vitro</span> studies in animals also suggest that paroxetine is a selective inhibitor of neuronal serotonin reuptake and has weak effects on norepinephrine and dopamine neuronal reuptake. <span class="Italics">In vitro</span> radioligand binding studies indicate that paroxetine has little affinity for muscarinic alpha<span class="Sub">1</span>-, alpha<span class="Sub">2</span>-, beta-adrenergic-, dopamine (D<span class="Sub">2</span>)-, 5-HT<span class="Sub">1</span>-, 5-HT<span class="Sub">2</span>-, and histamine (H<span class="Sub">1</span>)-receptors.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="SB123"></a><a name="section-11.3"></a><p></p>
<h2>12.3Â Â Â Â Â Â Pharmacokinetics</h2>
<p class="First"><span class="Underline">Absorption, Distribution, Metabolism and Excretion</span></p>
<dl>
<dt>Â </dt>
<dd>
<span class="Italics">Absorption</span><br><br>
</dd>
<dt>Â </dt>
<dd>Paroxetine is completely absorbed after oral dosing of the mesylate salt. In a study in which healthy postmenopausal women (n=24) received BRISDELLE 7.5 mg capsules as a daily dose for 14 days, steady-state paroxetine concentrations were achieved by approximately 12 days of dosing for most subjects, although it may take substantially longer in an occasional patient. Peak concentrations were reached at a median of 6 hours (3 to 8 hours range). Steady-state mean values of C<span class="Sub">max</span>, C<span class="Sub">min</span>, and AUC<span class="Sub">0-last</span> were 13.10 ng/mL (CV 91%), 7.17 ng/mL (CV 99%), and 237 hr*ng/mL (CV 94%), respectively. <br><br>
</dd>
<dt>Â </dt>
<dd>Steady-state AUC<span class="Sub">0-24</span> values were about 3 times those of AUC<span class="Sub">0-inf</span> following a single dose, indicating non-linear pharmacokinetics. Steady-state C<span class="Sub">max</span> values were approximately 5 times greater than those attained after a single dose and steady-state exposure based on AUC<span class="Sub">0-24</span> was about 10 times greater than AUC<span class="Sub">0-24</span>  after a single dose. <br><br>
</dd>
<dt>Â </dt>
<dd>The nonlinear kinetics and excess accumulation are due to the fact that CYP2D6, an enzyme that is in part responsible for paroxetine metabolism, is readily saturable. <br><br>
</dd>
<dt>Â </dt>
<dd>The effects of food on the bioavailability of paroxetine were studied with paroxetine tablets at higher strength. AUC was only slightly increased (6%) when drug was administered with food but the C<span class="Sub">max</span> was 29% greater, while the time to reach peak plasma concentration decreased from 6.4 hours post-dosing to 4.9 hours. BRISDELLE can be taken with or without food. <br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Italics">Distribution</span><br><br>
</dd>
<dt>Â </dt>
<dd>Paroxetine distributes throughout the body, including the central nervous system, with only 1% remaining in the plasma.<br><br>
</dd>
<dt>Â </dt>
<dd>Approximately 95% and 93% of paroxetine is bound to plasma protein at 100 ng/mL and 400 ng/mL, respectively. Under clinical conditions, paroxetine concentrations would normally be less than 100 ng/mL. Paroxetine does not alter the <span class="Italics">in vitro</span> protein binding of phenytoin or warfarin. <br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Italics">Metabolism</span><br><br>
</dd>
<dt>Â </dt>
<dd>Paroxetine is extensively metabolized after oral administration. The principal metabolites are polar and conjugated products of oxidation and methylation, which are readily cleared. Conjugates with glucuronic acid and sulfate predominate, and major metabolites have been isolated and identified. Data indicate that the metabolites have no more than 1/50 the potency of the parent compound at inhibiting serotonin uptake. The metabolism of paroxetine is accomplished in part by cytochrome CYP2D6. Saturation of this enzyme at clinical doses appears to account for the nonlinearity of paroxetine kinetics with increasing dose and increasing duration of treatment. The role of this enzyme in paroxetine metabolism also suggests potential drug-drug interactions <span class="Italics">[see Drug Interactions (<a href="#SB070">7</a>)]</span>. At steady state, when the CYP2D6 pathway is essentially saturated, paroxetine clearance is governed by alternative P450 isozymes, which, unlike CYP2D6, show no evidence of saturation. <br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Italics">Excretion</span><br><br>
</dd>
<dt>Â </dt>
<dd>Approximately 64% of a 30 mg oral solution of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites over a 10-day post-dosing period. About 36% of the dose was excreted in the feces (probably via the bile), mostly as metabolites and less than 1% as the parent compound over the 10-day post-dosing period. <br><br>
</dd>
</dl>
<p><span class="Underline">Specific Populations</span></p>
<dl>
<dt>Â </dt>
<dd>
<span class="Italics">Renal and Liver Impairment</span><br><br>
</dd>
<dt>Â </dt>
<dd>Increased plasma concentrations of paroxetine occur in subjects with renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The mean plasma concentration in patients with creatinine clearance below 30 mL/min was approximately 4 times greater than seen in normal volunteers. Patients with creatinine clearance of 30 to 60 mL/min and patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> had about a 2-fold increase in plasma concentrations (AUC, C<span class="Sub">max</span>). No BRISDELLE dose adjustment is considered necessary in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  <br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Italics">Elderly Patients </span><br><br>
</dd>
<dt>Â </dt>
<dd>In a multiple-dose study in the elderly at daily paroxetine doses of 20, 30, and 40 mg, C<span class="Sub">min</span> concentrations were about 70% to 80% greater than the respective C<span class="Sub">min</span> concentrations in nonelderly subjects. No BRISDELLE dose adjustment is considered necessary in elderly patients.<br><br>
</dd>
</dl>
<p><span class="Underline">Drug Interaction Studies</span></p>
<dl>
<dt>Â </dt>
<dd>
<span class="Italics">Potential Effect of BRISDELLE on Other Drugs</span><dl>
<dt>Â </dt>
<dd>
<br><span class="Bold">Drugs Metabolized by CYP3A4</span><br><br>
</dd>
<dt>Â </dt>
<dd>An <span class="Italics">in vivo</span> drug interaction study involving the co-administration under steady-state conditions of paroxetine and terfenadine, a substrate for cytochrome CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics. <span class="Italics">In vitro</span> studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for CYP3A4, including astemizole, triazolam, and cyclosporine. Based on the assumption that the relationship between paroxetineâ€™s <span class="Italics">in vitro</span> Ki and its lack of effect on terfenadineâ€™s <span class="Italics">in vivo</span> clearance predicts its effect on other CYP3A4 substrates, paroxetineâ€™s extent of inhibition of CYP3A4 activity is not likely to be of clinical significance.<br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Drugs Metabolized by CYP2D6</span><br><br>
</dd>
<dt>Â </dt>
<dd>Many drugs are metabolized by the cytochrome P450 isozyme CYP2D6. Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme. In most patients (&gt; 90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.<br><br>
</dd>
<dt>Â </dt>
<dd>Specific studies investigating the effect of paroxetine on drugs metabolized by CYP2D6 are listed below:<br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Pimozide:</span> Higher doses of paroxetine have been shown to elevate plasma levels of pimozide. In a controlled study of healthy volunteers, after paroxetine was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and C<span class="Sub">max</span> of 62%, compared to pimozide administered alone <span class="Italics">[see Drug Interactions (<a href="#SB071">7.1</a>)]</span>. <br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Tamoxifen:</span> It is uncertain whether the co-administration of paroxetine and tamoxifen has a significant adverse effect on the efficacy of tamoxifen. Some studies have shown that the efficacy of tamoxifen, as measured by the risk of breast cancer relapse/mortality, may be reduced when co-prescribed with paroxetine as a result of paroxetineâ€™s irreversible inhibition of CYP2D6. However, other studies have failed to demonstrate such a risk <span class="Italics">[see Warnings and Precautions (<a href="#SB053">5.3</a>) and Drug Interactions (<a href="#SB071">7.1</a>)]</span>.<br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Desipramine:</span> In one study, daily dosing of paroxetine (20 mg once daily) under steady-state conditions increased single dose desipramine (100 mg) C<span class="Sub">max</span>, AUC, and T<span class="Sub">1/2</span> by an average of approximately 2-, 5-, and 3-fold, respectively <span class="Italics">[see Drug Interactions (<a href="#SB071">7.1</a>)]</span>. <br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Risperidone:</span> Daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day), a CYP2D6 substrate, increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold <span class="Italics">[see Drug Interactions (<a href="#SB071">7.1</a>)]</span>. <br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Atomoxetine:</span> The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady-state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine C<span class="Sub">max</span> values that were 3- to 4-fold greater than when atomoxetine was given alone <span class="Italics">[see Drug Interactions (<a href="#SB071">7.1</a>)]</span>. <br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Digoxin:</span> Mean digoxin AUC at steady state decreased by 15% in the presence of paroxetine <span class="Italics">[see Drug Interactions (<a href="#SB071">7.1</a>)]</span>. <br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Beta Blockers:</span> In a study in which propranolol (80 mg twice daily) was dosed orally for 18 days, the steady-state plasma concentrations of propranolol were unaltered during co-administration with paroxetine (30 mg once daily) for the final 10 days. The effects of propranolol on paroxetine have not been evaluated.<br><br>
</dd>
</dl>
</dd>
<dt>Â </dt>
<dd>
<span class="Italics">Potential Effect of Other Drugs on BRISDELLE</span><dl>
<dt>Â </dt>
<dd>
<br>Concomitant use of paroxetine with other drugs that alter CYP enzymes activities including CYP2D6 may affect the plasma concentrations of paroxetine. Specific studies investigating the effect of other drugs on paroxetine are listed below:<br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Cimetidine: </span>Cimetidine inhibits many cytochrome P450 enzymes. In a study in which paroxetine (30 mg once daily) was dosed orally for 4 weeks, steady-state plasma concentrations of paroxetine were increased by approximately 50% during co-administration with oral cimetidine (300 mg three times daily) for the final week <span class="Italics">[see Drug Interactions (<a href="#SB072">7.2</a>)]</span>. <br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Phenobarbital: </span>Phenobarbital induces many cytochrome P450 enzymes. When a single oral 30 mg dose of paroxetine was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T<span class="Sub">1/2</span> were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone. The effect of paroxetine on phenobarbital pharmacokinetics was not studied. Because paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed <span class="Italics">[see Drug Interactions (<a href="#SB072">7.2</a>)]</span>.<br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Phenytoin: </span>When a single oral 30 mg dose of paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T<span class="Sub">1/2</span> were reduced (by an average of 50% and 35%, respectively) compared to paroxetine administered alone. In a separate study, when a single oral 300 mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone. Because both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed <span class="Italics">[see Drug Interactions (<a href="#SB072">7.2</a>)]</span>.<br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Digoxin: </span>A clinical drug interaction study showed that concurrent use of digoxin did not affect paroxetine exposure. <br><br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Diazepam: </span>A clinical drug interaction study showed that concurrent use of diazepam did not affect paroxetine exposure.</dd>
</dl>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="SB130"></a><a name="section-12"></a><p></p>
<h1>13Â Â Â Â Â Â NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="SB131"></a><a name="section-12.1"></a><p></p>
<h2>13.1Â Â Â Â Â Â Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>Two-year carcinogenicity studies were conducted in rodents given paroxetine in the diet at 1, 5, and 25 mg/kg/day (mice) and 1, 5, and 20 mg/kg/day (rats). The doses used in these carcinogenicity studies were approximately 16 (mouse) and 26 (rat) times the MHRD for VMS. There was a significantly greater number of male rats in the high-dose group with reticulum cell <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span> (1/100, 0/50, 0/50, and 4/50 for control, low-, middle-, and high-dose groups, respectively) and a significantly increased linear trend across groups for the occurrence of lymphoreticular tumors in male rats. Female rats were not affected. Although there was a dose-related increase in the number of tumors in mice, there was no drug-related increase in the number of mice with tumors. The relevance of these findings to humans is unknown. </p>
<p><span class="Underline">Mutagenesis</span></p>
<p>Paroxetine produced no genotoxic effect in a battery of 5 <span class="Italics">in vitro</span> and 2 <span class="Italics">in vivo</span> assays that included the following: bacterial mutation assay, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> mutation assay, unscheduled DNA synthesis assay, and tests for cytogenetic aberrations <span class="Italics">in vivo</span> in mouse bone marrow and <span class="Italics">in vitro</span> in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and in a dominant lethal test in rats.</p>
<p><span class="Underline">Impairment of Fertility</span></p>
<p>A reduced pregnancy rate was found in reproduction studies in rats at a paroxetine dose of 15 mg/kg/day, which is 19 times the MRHD for VMS on an mg/m<span class="Sup">2</span> basis. Irreversible lesions occurred in the reproductive tract of male rats after dosing in toxicity studies for 2 to 52 weeks. These lesions consisted of vacuolation of epididymal tubular epithelium at 50 mg/kg/day and atrophic changes in the seminiferous tubules of the testes with arrested spermatogenesis at 25 mg/kg/day (65 times and 32 times the MHRD for VMS on an mg/m<span class="Sup">2</span> basis, respectively).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="SB140"></a><a name="section-13"></a><p></p>
<h1>14Â Â Â Â Â Â CLINICAL STUDIES</h1>
<p class="First">The efficacy of BRISDELLE as a treatment for moderate to severe VMS associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> was established in two Phase 3 studies (at a dose of 7.5 mg once daily at bedtime) in 1174 postmenopausal women with a minimum of 7-8  moderate to severe vasomotor symptoms per day at baseline (â‰¥ 50 per week) for 30 days prior to receiving study drug.</p>
<p>Study 1 was a 12-week, randomized, double-blind, placebo-controlled clinical trial with a total of 606 postmenopausal women (average age 55 years, 65% Caucasian and 33% African American, 18% surgically menopausal and 82% naturally menopausal).</p>
<p>Study 2 was a 24-week, randomized, double-blind, placebo-controlled clinical trial with a total of 568 postmenopausal women (average age 54 years, 76% Caucasian and 22% African American, 20% surgically menopausal and 81% naturally menopausal).</p>
<p>The co-primary efficacy endpoints for both studies were the reduction from baseline in VMS frequency and severity at Weeks 4 and 12. Data from Study 1 showed a statistically significant reduction from baseline in the frequency of moderate to severe vasomotor symptoms at Week 4 and Week 12 and a statistically significant reduction in the severity of moderate to severe VMS at Week 4 for BRISDELLE compared to placebo (<a href="#Table4">Table 4</a>). Data from Study 2 showed a statistically significant reduction from baseline in the frequency and severity of moderate to severe vasomotor symptoms at Week 4 and Week 12 for BRISDELLE compared to placebo (<a href="#Table5">Table 5</a>).</p>
<a name="Table4"></a><table width="100%">
<caption><span>Table 4  Â Â Â Â Â Â Study 1: Changes in the Daily Frequency and Daily Severity of Moderate to Severe VMS at Weeks 4 and 12 (MITT Population)</span></caption>
<tfoot><tr class="First Last"><td colspan="6">MITT population: all consented and randomized subjects with valid baseline daily hot flash diary data who had taken at least 1 dose of study medication and had at least 1 day of on-treatment daily hot flash diary data.  
										<br>* Treatment Difference: the difference between the median changes from baseline.
										<br><span class="Sup">#</span><span class="Italics">P</span>-value is obtained from rank-ANCOVA model.
									</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td>Â </td>
<td class="Botrule" align="center" colspan="2" valign="top">
<span class="Bold">Frequency</span><br><br>
</td>
<td>Â </td>
<td class="Botrule" align="center" colspan="2" valign="top">
<span class="Bold">Severity</span><br><br>
</td>
</tr>
<tr>
<td class="Botrule">Â </td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">BRISDELLE</span><br><br>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">Placebo</span><br><br>
</td>
<td class="Botrule">Â Â Â Â Â Â Â </td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">BRISDELLE</span><br><br>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">Placebo</span><br><br>
</td>
</tr>
<tr>
<td><span class="Bold">Baseline</span></td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â n</td>
<td align="center">301</td>
<td align="center">305</td>
<td>Â </td>
<td align="center">301</td>
<td align="center">305</td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â Median</td>
<td align="center">10.4</td>
<td align="center">10.4</td>
<td>Â </td>
<td align="center">2.5</td>
<td align="center">2.5</td>
</tr>
<tr>
<td><span class="Bold Italics">Change from baseline at Week 4 </span></td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â n</td>
<td align="center">289</td>
<td align="center">293</td>
<td>Â </td>
<td align="center">281</td>
<td align="center">289</td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â Median</td>
<td align="center">-4.3</td>
<td align="center">-3.1</td>
<td>Â </td>
<td align="center">-0.05</td>
<td align="center">0.00</td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â Treatment Difference*</td>
<td align="center">-1.2</td>
<td align="center">Â </td>
<td>Â </td>
<td align="center">-0.05</td>
<td align="center">Â </td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â <span class="Italics">P</span>-value<span class="Sup">#</span>
</td>
<td align="center">&lt;0.01</td>
<td align="center">Â </td>
<td>Â </td>
<td align="center">&lt;0.01</td>
<td align="center">Â </td>
</tr>
<tr>
<td><span class="Bold Italics">Change from baseline at Week 12</span></td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â n</td>
<td align="center">264</td>
<td align="center">274</td>
<td>Â </td>
<td align="center">236</td>
<td align="center">253</td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â Median</td>
<td align="center">-5.9</td>
<td align="center">-5.0</td>
<td>Â </td>
<td align="center">-0.06</td>
<td align="center">-0.02</td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â Treatment Difference*</td>
<td align="center">-0.9</td>
<td align="center">Â </td>
<td>Â </td>
<td align="center">-0.04</td>
<td align="center">Â </td>
</tr>
<tr class="Last">
<td valign="top">Â Â Â Â Â Â Â Â Â <span class="Italics">P</span>-value<span class="Sup">#</span><br><br>
</td>
<td align="center" valign="top">&lt;0.01</td>
<td align="center" valign="top">Â </td>
<td>Â </td>
<td align="center" valign="top">0.17</td>
<td align="center" valign="top">Â </td>
</tr>
</tbody>
</table>
<a name="Table5"></a><table width="100%">
<caption><span>Table 5  Â Â Â Â Â Â Study 2: Changes in the Daily Frequency and Daily Severity of Moderate to Severe VMS at Weeks 4 and 12 (MITT Population)</span></caption>
<tfoot><tr class="First Last"><td colspan="6">MITT population: all consented and randomized subjects with valid baseline daily hot flash diary data who had taken at least 1 dose of study medication and had at least 1 day of on-treatment daily hot flash diary data.  
										<br>* Treatment Difference: the difference between the median changes from baseline.
										<br><span class="Sup">#</span><span class="Italics">P</span>-value is obtained from rank-ANCOVA model.
									</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td>Â </td>
<td class="Botrule" align="center" colspan="2" valign="top">
<span class="Bold">Frequency</span><br><br>
</td>
<td>Â </td>
<td class="Botrule" align="center" colspan="2" valign="top">
<span class="Bold">Severity</span><br><br>
</td>
</tr>
<tr>
<td class="Botrule">Â </td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">BRISDELLE</span><br><br>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">Placebo</span><br><br>
</td>
<td class="Botrule">Â Â Â Â Â Â Â </td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">BRISDELLE</span><br><br>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">Placebo</span><br><br>
</td>
</tr>
<tr>
<td><span class="Bold">Baseline</span></td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â n</td>
<td align="center">284</td>
<td align="center">284</td>
<td>Â </td>
<td align="center">284</td>
<td align="center">284</td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â Median</td>
<td align="center">9.9</td>
<td align="center">9.6</td>
<td>Â </td>
<td align="center">2.5</td>
<td align="center">2.5</td>
</tr>
<tr>
<td><span class="Bold Italics">Change from baseline at Week 4 </span></td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â n</td>
<td align="center">276</td>
<td align="center">274</td>
<td>Â </td>
<td align="center">268</td>
<td align="center">271</td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â Median</td>
<td align="center">-3.8</td>
<td align="center">-2.5</td>
<td>Â </td>
<td align="center">-0.04</td>
<td align="center">-0.01</td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â Treatment Difference*</td>
<td align="center">-1.3</td>
<td align="center">Â </td>
<td>Â </td>
<td align="center">-0.03</td>
<td align="center">Â </td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â <span class="Italics">P</span>-value<span class="Sup">#</span>
</td>
<td align="center">&lt;0.01</td>
<td align="center">Â </td>
<td>Â </td>
<td align="center">0.04</td>
<td align="center">Â </td>
</tr>
<tr>
<td><span class="Bold Italics">Change from baseline at Week 12</span></td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â n</td>
<td align="center">257</td>
<td align="center">244</td>
<td>Â </td>
<td align="center">245</td>
<td align="center">236</td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â Median</td>
<td align="center">-5.6</td>
<td align="center">-3.9</td>
<td>Â </td>
<td align="center">-0.05</td>
<td align="center">0.00</td>
</tr>
<tr>
<td>Â Â Â Â Â Â Â Â Â Treatment Difference*</td>
<td align="center">-1.7</td>
<td align="center">Â </td>
<td>Â </td>
<td align="center">-0.05</td>
<td align="center">Â </td>
</tr>
<tr class="Last">
<td valign="top">Â Â Â Â Â Â Â Â Â <span class="Italics">P</span>-value<span class="Sup">#</span><br><br>
</td>
<td align="center" valign="top">&lt;0.01</td>
<td align="center" valign="top">Â </td>
<td>Â </td>
<td align="center" valign="top">&lt;0.01</td>
<td align="center" valign="top">Â </td>
</tr>
</tbody>
</table>
<p>Persistence of benefit at 24 weeks in Study 2 was evaluated with a responder analysis where responders were defined as those patients who achieved â‰¥ 50% reduction from baseline in the frequency of moderate to severe VMS at Week 24. The proportion of patients achieving a â‰¥ 50% reduction in the frequency of moderate to severe VMS from baseline to Week 24 was 48% in the BRISDELLE group and 36% in the placebo group at Week 24.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="SB160"></a><a name="section-14"></a><p></p>
<h1>16Â Â Â Â Â Â HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">BRISDELLE is available as 7.5 mg pink capsules printed with black edible ink with â€œNOVENâ€? and â€œ7.5 mgâ€? on each capsule.</p>
<p>NDC 68968-9075-3, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 30</p>
<div class="Section" data-sectionCode="44425-7">
<a name="SB161"></a><a name="section-14.1"></a><p></p>
<p class="First">Store at 20Â°-25Â°C (68Â°-77Â°F); excursions permitted to 15Â°-30Â°C (59Â°-86Â°F). Protect from light and humidity.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="SB170"></a><a name="section-15"></a><p></p>
<h1>17Â Â Â Â Â Â PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-approved patient labeling (<a href="#SB171">Medication Guide</a>).</span></p>
<p>Instruct patients to read the Medication Guide before starting therapy with BRISDELLE and to reread it each time the prescription is renewed.<br><br></p>
<ul>
<li>Advise patients, their families, and their caregivers to look for the emergence of suicidality, especially early during treatment <span class="Italics">[see Boxed Warning and Warnings and Precautions (<a href="#SB051">5.1</a>)]</span>.<br><br>
</li>
<li>Instruct patients not to take BRISDELLE with an MAOI or within 14 days of stopping an MAOI and allow 14 days after stopping BRISDELLE before starting an MAOI <span class="Italics">[see Dosage and Administration (<a href="#SB022">2.2</a>) and Contraindications (<a href="#SB041">4.1</a>)]</span>.<br><br>
</li>
<li>Advise patients not to take BRISDELLE with thioridazine or pimozide <span class="Italics">[see Contraindications (<a href="#SB042">4.2</a> and <a href="#SB043">4.3</a>)]</span>.<br><br>
</li>
<li>Caution patients about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, particularly with the concomitant use of BRISDELLE with triptans, tricyclic antidepressants, linezolid, tramadol, St. Johnâ€™s Wort, lithium, tryptophan supplements, other serotonergic agents, or antipsychotic drugs <span class="Italics">[see Warnings and Precautions (<a href="#SB052">5.2</a>) and Drug Interactions (<a href="#SB073">7.3</a>)]</span>.<br><br>
</li>
<li>Caution patients that efficacy of tamoxifen may be reduced when administered concomitantly and counsel them about the likely benefit of paroxetine for treating VMS vs. the risk of possible decreased tamoxifen effectiveness <span class="Italics">[see Warnings and Precautions (<a href="#SB053">5.3</a>)]</span>.<br><br>
</li>
<li>Caution patients about the concomitant use of BRISDELLE and NSAIDs, aspirin, warfarin, and other anticoagulants because combined use of drugs that interfere with serotonin reuptake has been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#SB054">5.4</a>)]</span>.<br><br>
</li>
<li>Advise patients that taking BRISDELLE can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Pre-existing <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> is almost always open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> because angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, when diagnosed, can be treated definitively with iridectomy. Open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> is not a risk factor for angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> procedure (e.g., iridectomy), if they are susceptible  <span class="Italics">[See Warnings and Precautions (<a href="#SB055">5.5</a>)]</span>.<br><br>
</li>
<li>Caution patients about the risk of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, particularly elderly patients and those who are taking diuretics or are volume-depleted <span class="Italics">[see Warnings and Precautions (<a href="#SB056">5.6</a>)]</span>.<br><br>
</li>
<li>Inform patients that there is the possibility for an increased risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> <span class="Italics">[see Warnings and Precautions (<a href="#SB057">5.7</a>)]</span>.<br><br>
</li>
<li>Advise patients, their families, and their caregivers to observe for signs of activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> <span class="Italics">[see Warnings and Precautions (<a href="#SB058">5.8</a>)]</span>.<br><br>
</li>
<li>Advise patients to notify their physician if they become pregnant during therapy <span class="Italics">[see Contraindications (<a href="#SB045">4.5</a>) and Use in Specific Populations (<a href="#SB081">8.1</a>)]</span>.Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that paroxetine therapy does not affect their ability to engage in such activities <span class="Italics">[see Warnings and Precautions (<a href="#SB0511">5.11</a>)]</span>.<br><br>
</li>
<li>Advise patients to inform their healthcare provider if they are taking, or plan to take, any prescription or over-the-counter drugs, including herbal supplements, because there is a potential for interaction with paroxetine <span class="Italics">[see Drug Interactions (<a href="#SB073">7.3</a>)]</span>.<br><br>
</li>
<li>Advise patients that paroxetine, the active ingredient in BRISDELLE, is also the active ingredient in certain other drugs and these medications should not be taken concomitantly <span class="Italics">[see Indications and Usage (<a href="#SB010">1</a>) and Drug Interactions (<a href="#SB073">7.3</a>)]</span>.<br><br>
</li>
</ul>
<p>Distributed by: Noven Therapeutics, LLC, Miami, FL 33186.</p>
<p>BRISDELLE<span class="Sup">Â®</span> is a registered trademark of Noven Therapeutics, LLC.
							<br>Â© 2013-2014 Noven Therapeutics, LLC. All rights reserved.
						</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="SB171"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p>BRISDELLE<span class="Sup">Â®</span> (bris-del)</p>
<p>(Paroxetine)</p>
<p>Capsules</p>
<p>Read the Medication Guide that comes with BRISDELLE before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk with your healthcare provider if there is something you do not understand or want to learn more about.  BRISDELLE contains a lower dose of paroxetine, a medicine also used to treat a number of psychiatric disorders. The lower dose of paroxetine in BRISDELLE has not been studied in any psychiatric conditions and BRISDELLE is not approved for any psychiatric uses. </p>
<p><a name="SBMostImportant"></a><span class="Bold">What is the most important information I should know about BRISDELLE?</span></p>
<p>BRISDELLE may cause serious side effects. </p>
<p><span class="Bold">Call your healthcare provider right away if you have any of the following symptoms, or go to the nearest emergency room:</span></p>
<p><span class="Bold">1. Suicidal thoughts or actions: </span></p>
<ul class="Disc">
<li><span class="Bold">BRISDELLE, and related antidepressant medicines, may increase suicidal thoughts or actions within the first few months of treatment.</span></li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> or other serious mental illnesses are the most important causes of suicidal thoughts or actions.</li>
<li>Watch for these changes and call your healthcare provider right away if you notice:
								<ul class="Circle">
<li>New or sudden changes in mood, behavior, actions, thoughts, or feelings, especially if severe.</li>
<li>Pay particular attention to such changes when BRISDELLE is started.</li>
</ul>
</li>
</ul>
<dl>
<dt>Â </dt>
<dd>Keep all follow-up visits with your healthcare provider and call between visits if you are worried about symptoms.<br>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Call your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</span><ul class="Circle">
<li>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></li>
<li>acting on dangerous impulses</li>
<li>acting aggressive or violent</li>
<li>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></li>
<li>feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span>, angry or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span></li>
<li>trouble sleeping</li>
<li>an increase in activity or talking more than what is normal for you</li>
<li>other unusual changes in behavior or mood.</li>
</ul>
</dd>
</dl>
<p><span class="Bold">2. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>. This condition can be life-threatening and may include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> (<span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>), <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or other changes in mental status</li>
<li>coordination problems or <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span> (small movements of the muscles that you cannot control)</li>
<li>racing heartbeat, high or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> </li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span></li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
</ul>
<p><span class="Bold">3. Reduced effectiveness of tamoxifen. </span>Tamoxifen (a medicine used to treat breast cancer) may not work as well if it is taken while you take BRISDELLE.  If you are taking tamoxifen, tell your healthcare provider before starting BRISDELLE.</p>
<p><span class="Bold">4. Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </span>BRISDELLE may increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, especially if you take the blood thinner warfarin or non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, naproxen, or aspirin.</p>
<p><span class="Bold">5. Visual problems. </span><br>
							Â Â â€¢Â Â <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">Eye pain</span><br>Â Â â€¢Â Â Changes in vision Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€¢Â Â <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> in or around the eye<br>Â Â Only some people are at risk for these problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are.</p>
<p><span class="Bold">6. Low salt (sodium) levels in the blood. </span>Elderly people may be at greater risk for this condition. Symptoms may include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or feeling unsteady</li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, problems concentrating or thinking or memory problems.</li>
</ul>
<p><span class="Bold">7. Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span>.  </span>Women who take BRISDELLE may have a higher risk of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>.  Contact your healthcare provider if you have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in a bone.</p>
<p><span class="Bold">8. <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic episodes</span>:</span></p>
<ul>
<li>greatly increased energy</li>
<li>severe trouble sleeping</li>
<li><span class="product-label-link" type="condition" conceptid="4115026" conceptname="Racing thoughts">racing thoughts</span></li>
<li>reckless behavior</li>
<li>unusually grand ideas</li>
<li>excessive happiness or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li>talking more or faster than usual.</li>
</ul>
<p><span class="Bold">9. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</span></p>
<p><span class="Bold">10. <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>. </span>Women who take BRISDELLE may feel an inner <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> (<span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>), or be unable to sit still or stand still especially when they start taking BRISDELLE.  Call your healthcare provider if this happens to you.</p>
<p><span class="Bold">11. Driving.  </span>BRISDELLE may affect your ability to make decisions, think clearly, or react quickly.  Do not drive, operate heavy machinery, or do other potentially dangerous activities until you know how BRISDELLE affects you.</p>
<p><span class="Bold">What is BRISDELLE?</span></p>
<p>BRISDELLE is a prescription medicine used to reduce moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. BRISDELLE is a selective serotonin reuptake inhibitor (SSRI).  It is not a hormone. The way BRISDELLE treats <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> is not known. BRISDELLE does not prevent or treat <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> or dryness, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> or burning in and around the vagina.</p>
<p>BRISDELLE is not for psychiatric problems such as <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span>, <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">panic disorder</span>, <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">generalized anxiety disorder</span>, <span class="product-label-link" type="condition" conceptid="440690" conceptname="Social phobia">social anxiety disorder</span>, and post-traumatic stress disorder.  </p>
<p>BRISDELLE is not for use in children.</p>
<p>Talk to your healthcare provider if you do not think that your <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> are getting better while taking BRISDELLE.</p>
<p><span class="Bold">Who should not take BRISDELLE?</span></p>
<p>Do not take BRISDELLE if you:</p>
<ul>
<li>
<span class="Bold">take a Monoamine Oxidase Inhibitor (MAOI). </span>Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid. 
								<ul>
<li>Do not take an MAOI within 14 days of stopping BRISDELLE unless directed to do so by your healthcare provider.</li>
<li>Do not start BRISDELLE if you stopped taking an MAOI in the last 14 days unless directed to do so by your healthcare provider.</li>
<li>
<span class="Bold">People who take BRISDELLE close in time to an MAOI may have serious or life-threatening side effects. Get medical help right away if you have any of these symptoms:</span><ul class="LittleSquare">
<li>high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li>uncontrolled <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span></li>
<li>stiff muscles</li>
<li>rapid changes in heart rate or blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> (pass out)</li>
</ul>
</li>
</ul>
</li>
<li>
<span class="Bold">take thioridazine. </span>Do not take thioridazine together with BRISDELLE because this can cause serious heart rhythm problems or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>.</li>
<li>
<span class="Bold">take the antipsychotic medicine pimozide. </span>Do not take pimozide together with BRISDELLE because this can cause serious heart problems.</li>
<li><span class="Bold">are allergic to paroxetine or any of the ingredients in BRISDELLE.  See the end of this Medication Guide for a complete list of ingredients in BRISDELLE. </span></li>
<li>
<span class="Bold">are pregnant. </span>BRISDELLE is not for pregnant women. Paroxetine, the active ingredient in BRISDELLE, can harm your unborn baby. Risks to your unborn baby include an increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, particularly heart defects. Your baby may also have certain other serious symptoms shortly after birth.</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking BRISDELLE? </span></p>
<p><span class="Bold">Before starting BRISDELLE, tell your healthcare provider if you:</span></p>
<ul>
<li>have liver problems</li>
<li>have kidney problems</li>
<li>have or had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span></li>
<li>have bipolar disorder or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span></li>
<li>have low sodium levels in your blood</li>
<li>have or had <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
<li>have <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (high pressure in the eye)</li>
<li>have any other medical conditions</li>
<li>
<span class="Bold">are breastfeeding or plan to breastfeed. </span>BRISDELLE passes into breast milk. Talk to your healthcare provider before taking BRISDELLE if you are breast-feeding.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines that you take</span>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. BRISDELLE and some medicines may interact with each other, may not work as well, or may cause serious side effects when taken together.</p>
<table><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">If you take BRISDELLE, you should not take any other medicines that contain paroxetine, Â Â Â Â Â Â <br>including Paxil, Paxil CR and Pexeva.  </td></tr></tbody></table>
<p><span class="Bold">Especially tell your healthcare provider if you take:</span></p>
<ul>
<li>triptans used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span></li>
<li>medicines used to treat mood, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> or thought disorders, including MAOIs, SSRIs, tricyclics, lithium, buspirone, or antipsychotics</li>
<li>tramadol, fentanyl or over-the-counter supplements such as tryptophan or St. Johnâ€™s Wort</li>
<li>thioridazine</li>
<li>pimozide</li>
<li>tamoxifen</li>
<li>atomoxetine</li>
<li>cimetidine</li>
<li>digoxin</li>
<li>theophylline</li>
<li>medicines to treat irregular heart rate (like propafenone, flecainide, and encainide)</li>
<li>medicines used to treat <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span></li>
<li>certain medicines used to treat <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span></li>
<li>the blood thinner warfarin</li>
<li>nonsteroidal anti-inflammatory drugs (NSAIDs) (like ibuprofen, naproxen, or aspirin)</li>
<li>certain medicines used to treat <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (like phenobarbital and phenytoin)</li>
<li>other drugs containing paroxetine, the medicine in BRISDELLE.</li>
</ul>
<p>Ask your healthcare provider if you are not sure if you are taking any of these medications.</p>
<p>Your healthcare provider or pharmacist can tell you if it is safe to take BRISDELLE with your other medicines.  Do not start or stop any medicine while taking BRISDELLE without talking to your healthcare provider first.</p>
<p><span class="Bold">How should I take BRISDELLE?</span></p>
<ul>
<li>Take BRISDELLE exactly as your healthcare provider tells you to take it.</li>
<li>Take BRISDELLE 1 time each day at bedtime.</li>
<li>BRISDELLE may be taken with or without food.</li>
<li>If you miss a dose of BRISDELLE, take the missed dose as soon as you remember.  If it is almost time for the next dose, skip the missed dose and take your next dose at the regular time.  Do not take two doses of BRISDELLE at the same time.</li>
<li>If you take too much BRISDELLE, call your healthcare provider or poison control center right away, or go to the nearest emergency room right away.</li>
</ul>
<p><span class="Bold">What should I avoid while taking BRISDELLE?</span></p>
<ul><li>BRISDELLE can cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or may affect your ability to make decisions, think clearly, or react quickly. You should not drive, operate heavy machinery, or do other dangerous activities until you know how BRISDELLE affects you.</li></ul>
<p><span class="Bold">What are the possible side effects of BRISDELLE?</span></p>
<p><span class="Bold">BRISDELLE may cause serious side effects, including: </span></p>
<ul><li>See â€œ<a href="#SBMostImportant">What is the most important information I should know about BRISDELLE?</a>â€?</li></ul>
<p>The most common side effects of BRISDELLE include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or does not go away.  These are not all the possible side effects of BRISDELLE.  For more information, ask your healthcare provider or pharmacist.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">How should I store BRISDELLE?</span></p>
<ul>
<li>Store BRISDELLE at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</li>
<li>Keep BRISDELLE out of the light. </li>
<li>Keep BRISDELLE dry.</li>
<li><span class="Bold">Keep BRISDELLE and all medicines out of the reach of children.</span></li>
</ul>
<p><span class="Bold">General information about the safe and effective use of BRISDELLE.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BRISDELLE for a condition for which it was not prescribed.  Do not give BRISDELLE to other people, even if they have the same condition. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about BRISDELLE.  If you would like more information, talk with your healthcare provider.  You may ask your healthcare provider or pharmacist for information about BRISDELLE that is written for healthcare professionals.</p>
<p>For more information about BRISDELLE call 1-800-455-8070 or go to <span class="Underline">www.BRISDELLE.com</span>.</p>
<p><span class="Bold">What are the ingredients in BRISDELLE?</span></p>
<p><span class="Bold">Active ingredient: </span>paroxetine</p>
<p><span class="Bold">Inactive ingredients: </span>dibasic calcium phosphate, sodium starch glycolate, magnesium stearate, gelatin, titanium dioxide, FD&amp;C Yellow #6, FD&amp;C Red #3, FD&amp;C Red #40, shellac and black iron oxide.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Distributed by: Noven Therapeutics, LLC, Miami, FL 33186.</p>
<p>BRISDELLE<span class="Sup">Â®</span> is a registered trademark of Noven Therapeutics, LLC.<br>Â© 2013-2014 Noven Therapeutics, LLC. All rights reserved.</p>
<p>Revised 12/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SB180"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - NDC: 68968-9075-3 - 30-Capsule <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card</span></p>
<p><img alt="30-capsule <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf208751-e6d8-11e1-aff1-0800200c9a66&amp;name=brisdelle-figure-2.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SB181"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - NDC: 68968-9075-3 - <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</span></p>
<p><img alt="<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf208751-e6d8-11e1-aff1-0800200c9a66&amp;name=brisdelle-figure-3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BRISDELLEÂ 		
					</strong><br><span class="contentTableReg">paroxetine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68968-9075</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PAROXETINE MESYLATE</strong> (PAROXETINE) </td>
<td class="formItem">PAROXETINE</td>
<td class="formItem">7.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (PINK) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NOVEN;7;5;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68968-9075-3</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204516</td>
<td class="formItem">06/28/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Noven Therapeutics, LLC
							(166888268)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Norwich Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">132218731</td>
<td class="formItem">MANUFACTURE(68968-9075), ANALYSIS(68968-9075), PACK(68968-9075), LABEL(68968-9075)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Quality Chemical Laboratories</td>
<td class="formItem"></td>
<td class="formItem">071344167</td>
<td class="formItem">ANALYSIS(68968-9075)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Packaging Coordinators, LLC</td>
<td class="formItem"></td>
<td class="formItem">078525133</td>
<td class="formItem">PACK(68968-9075), LABEL(68968-9075)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sharp Corporation</td>
<td class="formItem"></td>
<td class="formItem">002346625</td>
<td class="formItem">PACK(68968-9075)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Anderson Brecon Packaging, Inc.</td>
<td class="formItem"></td>
<td class="formItem">053217022</td>
<td class="formItem">PACK(68968-9075)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Excella GmbH</td>
<td class="formItem"></td>
<td class="formItem">329809800</td>
<td class="formItem">API MANUFACTURE(68968-9075), ANALYSIS(68968-9075)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1125def0-7aa3-11e4-82f8-0800200c9a66</div>
<div>Set id: bf208751-e6d8-11e1-aff1-0800200c9a66</div>
<div>Version: 6</div>
<div>Effective Time: 20141204</div>
</div>
</div>Â <div class="DistributorName">Noven Therapeutics, LLC</div></p>
</body></html>
